TRIAL DATA
Maintenance immunotherapy after complete response may not be necessary in dMMR/MSI-H rectal cancerA multicenter cohort study of 129 patients who entered non-operative management after achieving clinical complete response with PD-1 inhibitors found 3-year disease-free survival was 96.2% with observation versus 98.3% with maintenance therapy, with no significant difference. (J Immunother Cancer)